Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


As you may recall, the key thing my doctor—and I—would like to see on the multiple myeloma front is a big drop in my M protein level, a marker for cancerous plasma cells. Today we got the latest results, and it’s up to 0.9. Since the first round of chemotherapy had already gotten it down to 1.0, what this means is that the entire second round of chemotherapy at City of Hope was basically useless. I didn’t respond to it at all.

We went ahead with the biopsy today anyway, for reasons that are a little vague to me. Apparently it will give us some indication of where the cancerous cells are, but the results won’t have any impact on my treatment plan. In a couple of days I’ll start on a low daily dose of Revlimid, in hopes that it will get my M protein level down to zero. If it doesn’t, then we’ll try a higher dose.

Revlimid is a highly controlled substance because it’s in the same family as thalidomide and can cause serious birth defects. You cannot just pick it up at your local pharmacy. First, you have to fill out a lengthy form, and the medication is then mailed from a central location, presumably in a plain brown wrapper or something. As near as I could tell, pretty much every question on the form was some variation of me promising not to even think about getting anyone pregnant while I’m taking it. As you can imagine, this is not really an issue, so the form turned out not to be too much of a chore after all. It was just OK, OK, OK, OK, etc. I promise.

So that’s it for now. Not exactly cheery news, but the buildup of cancerous cells in my bone marrow is not actually that heavy (about 5 percent or so), which means there’s a decent chance the Revlimid will be enough to keep it under control. We’ll know in a couple of months or so.

Fact:

Mother Jones was founded as a nonprofit in 1976 because we knew corporations and billionaires wouldn't fund the type of hard-hitting journalism we set out to do.

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation today so we can keep on doing the type of journalism 2022 demands.

payment methods

Fact:

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation today so we can keep on doing the type of journalism 2022 demands.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate